teaser
Important Phase III data from ATLAS ACS 2-TIMI 51 Study on secondary ACS prevention in higher risk, ST-Elevation Myocardial Infarction (STEMI) patients will be highlighted in a Clinical Trial and Registry Update Session
Further sub-analyses from the successful 14,000 patient Phase III ROCKET AF Trial of rivaroxaban in patients with non-valvular Atrial Fibrillation (AF) will also be presented
Independently, the Thrombosis Research Institute (TRI) will present data from the GARFIELD Registry, an academic research initiative, supported through an unrestricted educational grant from Bayer
